All posts by aclasuperadmin
Connecting Patients with The Treatment They Need
Kavita Bhat, PhD, is the Vice President of Lab Operations at Myriad Neuroscience, a subsidiary of Myriad Genetics. In her role, Dr. Bhat works closely with her colleagues to perform pharmacogenetic (PGx) testing – a type of genetic test that provides doctors and patients with vital clinical information to inform care.
Providers rely on PGx tests to identify genetic markers and clinically actionable information that can anticipate a patient’s response to drugs based on well-documented scientific evidence. By helping providers pinpoint potential adverse drug reactions and response markers, PGx testing helps limit the significant costs associated with trial and error and supports a more efficient, patient-centered approach to care. As Dr. Bhat notes, this is particularly important for patients managing mental health conditions – the focus of her lab – given the health complications that may arise if a patient isn’t prescribed a medication compatible with their genetic makeup.
Dr. Bhat also shares how ongoing genetic innovations can play a critical role in making health care delivery more efficient, lowering patients’ costs, and improving their access to appropriate treatments. Given the direct role and value that these tests provide, “We really need to continue investing in research and development in order to provide better quality and improved outcomes,” emphasizes Dr. Bhat. “We’re all trying to improve care.”
Watch below for highlights from the interview with Dr. Bhat and learn more about the critical work performed by laboratory professionals across the country.
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
Multiplex Testing: An Important Tool To Counter the Spread of Flu and COVID-19
A key part of the country’s ability to track and stop the spread of this virus and other infectious diseases is the continued development and evolution of novel testing methods that can address the diverse health needs of patients across the country. The recent introduction of multiplex testing is the latest example of the industry tackling two prominent public health threats: COVID-19 and influenza.
Influenza impacts millions of individuals annually in the United States. In fact, the Centers for Disease Control (CDC) estimates that as many as 9.3 to 45 million people are infected by influenza each year, resulting in 140,000 – 810,000 hospitalizations and 12,000 – 61,000 deaths. Among those most susceptible to complications from the flu are older Americans over 65 years old, individuals with chronic conditions, pregnant women, young children and marginalized racial groups.
Multiplex testing is used for targeted cases as determined by a clinician, and is not a replacement for standard COVID-19 testing. For certain patients, such as those presenting with multiple symptoms associated with respiratory viral infections, multiplex testing allows providers to test for multiple viruses at once and provide a more comprehensive clinical diagnosis.
According to the CDC, patients may experience concurrent respiratory infections, making accurate identification of these viruses through a single diagnostic test even more important as the country faces a new surge of COVID-19 cases on top of flu season. Distinguishing these viruses is significant as they do not share the same treatment or public health implications, further underscoring the important role of multiplex testing for our broader public health response to the pandemic.
Though multiplex testing has played a key role in past flu seasons, several ACLA member laboratories have pioneered new multiplex tests to help providers quickly differentiate between SARS-CoV-2, influenza A, influenza B, RSV and other respiratory viruses that may have similar or overlapping symptoms.
Multiplex testing also helps clinical labs conserve important testing supplies, such as pipettes, swabs and reagents, all of which remain in high demand. By reducing the need for single-use testing, multiplex testing also decreases the consumption of critical testing supplies while delivering accurate and comprehensive results to both patients and providers. During continued high demand for COVID-19 tests and supply chain constraints, multiplex testing is vital to creating workflow efficiencies for clinical labs and streamlining test orders for patients, providers and public health authorities.
As the COVID-19 pandemic continues alongside peak flu season, it is critical that Congress strengthen the federal protections that allow patients to access critical diagnostic tests without cost-sharing. Multiplex testing remains an essential tool for providers, patients and public health officials to help manage this challenging flu season and the continued spread of COVID-19.
ACLA Letter on COVID Vaccine Distribution
ACLA Comments on Medicare and Medicaid Programs, Clinical Laboratory Improvement Amendments and Patient Protection and Affordable Care Act Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency [CMS-3401-IFC]
ACLA Comments on 2021 ONC Interoperability Standards Advisory (ISA)
ACLA Update on PCR Testing Capacity For COVID-19
WASHINGTON, D.C. – As COVID-19 cases continue to surge across the United States, ACLA President Julie Khani issued the following statement:
“Yesterday, ACLA member laboratories collectively performed 495,000 COVID-19 PCR tests, reflecting an all-time daily high for our members. We continue to do all that we can to expand testing capacity and provide test results to patients, health care providers and public health agencies as quickly as possible. With demand for testing surging across the country, ACLA member laboratories are experiencing a significant increase in the volume of COVID-19 test orders. Clinical labs are also facing delays or cancellations on orders for critical supplies, such as pipette tips. In addition, specimen pooling, one of the many techniques labs have developed to more efficiently use supplies and increase capacity, is only applicable for populations at low risk or with low prevalence of infection, and is therefore currently limited due to increased positivity rates in communities across the country.
The surge in demand for testing will mean that some members could reach or exceed their current testing capacities in the coming days. In cases where the number of specimens received exceeds an individual laboratory’s testing capacity, there could be an increase in their average time to deliver results.
As we near the upcoming Thanksgiving holiday and anticipate continued demand for testing, we encourage communities to heed the advice of public health officials, such as practicing safe social distancing, wearing masks and postponing non-essential travel. Testing is a vital facet of a public health strategy, but testing alone is not going to stop the spread of the virus. We must take the actions necessary to contain the virus in all communities.”
###
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers. ACLA members are at the forefront of driving diagnostic innovation to meet the country’s evolving health care needs and provide vital clinical laboratory tests that identify and prevent infectious, acute and chronic disease. ACLA works to advance the next generation of health care delivery through policies that expand access to lifesaving testing services.
ACLA Update on PCR Testing Capacity For COVID-19
WASHINGTON, D.C. – As COVID-19 cases continue to surge across the United States, ACLA President Julie Khani issued the following statement:
“Yesterday, ACLA member laboratories collectively performed 495,000 COVID-19 PCR tests, reflecting an all-time daily high for our members. We continue to do all that we can to expand testing capacity and provide test results to patients, health care providers and public health agencies as quickly as possible. With demand for testing surging across the country, ACLA member laboratories are experiencing a significant increase in the volume of COVID-19 test orders. Clinical labs are also facing delays or cancellations on orders for critical supplies, such as pipette tips. In addition, specimen pooling, one of the many techniques labs have developed to more efficiently use supplies and increase capacity, is only applicable for populations at low risk or with low prevalence of infection, and is therefore currently limited due to increased positivity rates in communities across the country.
The surge in demand for testing will mean that some members could reach or exceed their current testing capacities in the coming days. In cases where the number of specimens received exceeds an individual laboratory’s testing capacity, there could be an increase in their average time to deliver results.
As we near the upcoming Thanksgiving holiday and anticipate continued demand for testing, we encourage communities to heed the advice of public health officials, such as practicing safe social distancing, wearing masks and postponing non-essential travel. Testing is a vital facet of a public health strategy, but testing alone is not going to stop the spread of the virus. We must take the actions necessary to contain the virus in all communities.”
###
The American Clinical Laboratory Association (ACLA) is the national trade association representing leading laboratories that deliver essential diagnostic health information to patients and providers. ACLA members are at the forefront of driving diagnostic innovation to meet the country’s evolving health care needs and provide vital clinical laboratory tests that identify and prevent infectious, acute and chronic disease. ACLA works to advance the next generation of health care delivery through policies that expand access to lifesaving testing services
Serologic testing provides a surveillance strategy for the fight against COVID-19
Since the start of this public health crisis, ACLA member laboratories have developed and expanded a range of tests and methods to support patients – including the first at-home specimen collection kits, COVID-19 specimen pooling and the launch of novel RNA extraction methods. Separate from tests used to determine an active infection, the use of serologic or antibody testing analyzes a patients’ blood specimen for the presence of immune response proteins developed due to a viral exposure or infection. In addition to its use in developing therapeutics and as a vital tool in vaccine trials, widespread serologic testing helps experts determine the number of individuals exposed or infected with COVID-19. Also, it provides valuable information to support broader prevention, containment and mitigation strategies.
Specifically, serologic testing is a valuable surveillance tool to help public health experts learn about the level of exposure to a virus in a community. Serologic testing can also be a critical asset in determining resource allocation and public health interventions’ effectiveness in a pandemic. While we continue to study the science around the exact level or the duration of immunity against reinfection that SARS-CoV-2 antibodies may provide, we know that accurate and reliable serologic testing is fundamental to our national response efforts.
In July, researchers from Ascend Clinical, an ACLA member laboratory specializing in testing services for kidney disease, began collaborating with the Stanford University School of Medicine to understand the seroprevalence – the number of individuals who test positive for a certain disease – of SARS-CoV-2 antibodies across large populations. While the study focused specifically on patients receiving dialysis treatment, many of its findings have significant implications for the general population.
Researchers collected information from more than 28,000 randomly selected dialysis patients from across the United States. Ascend Clinical performed testing using the Siemens Atellica IM SARS-CoV-2 Total (COV2T) antibody assay and discovered that there were higher rates of SARS-CoV-2 antibodies in Black and Hispanic patients as well as those living in densely populated areas. The study also found significant regional variation – from less than 5 percent in the West to greater than 25 percent in the Northeast.
As of July, researchers from Ascend and Stanford estimated that fewer than 10 percent of U.S. adults possessed SARS-CoV-2 antibodies – a figure well below what experts say is necessary for herd immunity. The dialysis population may be ideal for studying the general spread of COVID-19 in the U.S. because these patients undergo monthly, routine blood draws and represent other similar COVID-19 risk factors. As the COVID-19 pandemic continues, applying these findings and the results from serologic testing to bolster our surveillance efforts can help tailor public health strategies and meet the needs of the most vulnerable communities impacted by COVID-19.
